The Imexpharm Pharmaceutical Joint Stock Company recently announced that it had been honored as a listed company with one of the top 20 best annual reports in the non-financial sector and one of the top 10 best company managements in the mid-cap group.

This was the result of the annual Voting for Listed Enterprises, organized by the Ho Chi Minh Stock Exchange, the Hanoi Stock Exchange, Dragon Capital, and the Investment Newspaper. Voting aimed to honor companies that have demonstrated good corporate governance and management practices through the internal disclosure of information and communication channels with market regulatory agencies.

The Organizing Committee’s assessment reveals that annual reports and corporate governance honored can be viewed as models for other businesses to refer to. It can also form the basis for policymakers and State management agencies to improve general and detailed standards to effectively manage and operate businesses, sectors, and industries, to strengthen national competitiveness.

This is a proud result that recognizes Imexpharm’s efforts to become a listed company with professional, transparent operations that always comply with and meet international standards and practices in financial reporting, auditing, and corporate governance.

The results of Voting for Listed Enterprises were announced on December 15 in Cam Ranh city in south-central Khanh Hoa province, evaluating and encouraging listed companies to improve their professionalism, transparency, and ability to convey information in their annual reports, financial reports, and sustainable development reports, and to increase the ability of investors to access information on listed companies. It also helps assess the implementation of corporate governance by listed companies based on reliable information that companies publicly disclose to regulators and investors, and encourages the application of international standards and practices on corporate governance.

According to the Organizing Committee, this year a total of 116 annual reports were evaluated, of which 24 came from the financial sector and 92 from the non-financial sector.

General Director of Imexpharm, People’s Doctor, Pharmacist Tran Thi Dao said that as a pharmaceutical company that was listed on the stock exchange in 2006, Imexpharm pursued a goal of becoming a sustainable, professional, and transparent company in all activities, especially in governance. “This result is recognition of Imexpharm’s efforts and increases the trust of customers, shareholders, and investors.”

Dr. Dao also noted that in sustainable development, Imexpharm has invested deeply in product quality while ensuring reasonable prices for patients. Quality is an outstanding point of Imexpharm that has been recognized by hospitals, doctors, and patients in recent years. “We always maintain an international-standard production system, focus our resources, and invest systematically in manufacturing plants that meet EU-GMP and other advanced international standards,” she said.

Looking back at the first eleven months of this year, Imexpharm has made strong strides forward in its business operations in the context of the domestic economy still facing many difficulties two years after Covid-19. Imexpharm’s total revenue in November reached VND230.3 billion ($9.55 million), up 11.9 per cent year-on-year. In the first eleven months, it posted net revenue of VND1.78 trillion ($74.09 million) and pre-tax profits of VND360.6 billion ($14.91 million), up 23.2 per cent and 36.2 per cent, respectively, compared to the same period of 2022.

Imexpharm therefore achieved 102.2 per cent of its revenue plan and 103 per cent of its profit target proposed at the 2023 Annual General Meeting of Shareholders (AGM). These are impressive business results and testament to Imexpharm’s sustainable and efficient growth.

To continue this growth, the company will focus on effectively controlling strategic goals using the BSC (Balanced Scorecard) tool for each block and accelerating the progress of completing the 2023 plan proposed by the AGM. It will also closely monitor the production plan at factories to ensure that this meets demand for market items at the end of the year. At the same time, it will closely control and manage inventory, ensuring the effectiveness of the reserve plan at a safe level for both finished products and production materials to meet business plans and market needs. Imexpharm will also review the financial plan, including budget and cash flow, to ensure that it has sufficient resources to maintain stable operations in the fourth quarter and into the new year.

Established in 1977 in the Mekong Delta’s Dong Thap province, Imexpharm has always prioritized quality in providing high-quality, safe, and effective healthcare products for patients and the community.

It has four manufacturing clusters, including three EU-GMP manufacturing clusters with eleven production lines that meet EU-GMP standards. This has made Imexpharm the largest pharmaceutical manufacturing company with EU-GMP manufacturing clusters and with the largest number of EU-GMP production lines. It is currently a manufacturing partner of many leading multinational pharmaceutical corporations, such as Sandoz, DP Pharma, Galien, Pharmacience Canada, and Sanofi - Aventis. As of the end of 2022, it had obtained 12 registrations for seven products in Europe.

For more detailed information, please visit: https://imexpharm.com/.